The estimated Net Worth of Shreeram Aradhye is at least $3.95 million dollars as of 15 December 2021. Shreeram Aradhye owns over 2,837 units of Axcella Health Inc stock worth over $35,751 and over the last 5 years he sold AXLA stock worth over $0. In addition, he makes $3,911,720 as Executive Vice President et Chief Development Officer at Axcella Health Inc.
Sign up
Shreeram Aradhye AXLA stock SEC Form 4 insiders trading
Shreeram has made over 2 trades of the Axcella Health Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 2,837 units of AXLA stock worth $12,993 on 15 December 2021.
The largest trade he's ever made was exercising 7,025 units of Axcella Health Inc stock on 15 September 2021 worth over $32,175. On average, Shreeram trades about 1,233 units every 11 days since 2019. As of 15 December 2021 he still owns at least 7,806 units of Axcella Health Inc stock.
You can see the complete history of Shreeram Aradhye stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Shreeram Aradhye biography
Dr. Shreeram Aradhye M.D. serves as Executive Vice President, Chief Development Officer of the Company. Prior to joining us, Dr. Aradhye built an accomplished career at Novartis Pharmaceuticals Corporation. For over two decades, he served in multiple leadership roles of increasing responsibility in Development and Medical Affairs, across multiple therapeutic areas and geographies. In his most recent role as CMO of Novartis, he was a member of the Global Pharmaceuticals Executive Committee responsible for over $20 billion in worldwide business, provided medical expertise on portfolio strategy and led governance of medical activities worldwide. Dr. Aradhye was also a Member of the Development Committee of Novartis that oversaw global development activities across its portfolio. In previous roles at Novartis and Sandoz, he led the clinical development program for Gilenya® in MS, provided functional leadership for clinical development and medical affairs teams working on novel and biosimilar medicines across multiple therapeutic areas and headed Global Development for Neuroscience, where he oversaw a portfolio of programs in MS, Alzheimer's Disease, neuropathic pain, muscle disease and migraine. Prior to industry, Dr. Aradhye was Assistant Professor of Medicine and a transplant nephrologist at the University of Pennsylvania.
What is the salary of Shreeram Aradhye?
As the Executive Vice President et Chief Development Officer of Axcella Health Inc, the total compensation of Shreeram Aradhye at Axcella Health Inc is $3,911,720. There are no executives at Axcella Health Inc getting paid more.
How old is Shreeram Aradhye?
Shreeram Aradhye is 57, he's been the Executive Vice President et Chief Development Officer of Axcella Health Inc since 2019. There are 4 older and 11 younger executives at Axcella Health Inc. The oldest executive at Axcella Health Inc is Catherine Sohn, 67, who is the Independent Director.
What's Shreeram Aradhye's mailing address?
Shreeram's mailing address filed with the SEC is C/O DICERNA PHARMACEUTICALS, INC., 75 HAYDEN AVENUE, LEXINGTON, MA, 02421.
Insiders trading at Axcella Health Inc
Over the last 5 years, insiders at Axcella Health Inc have traded over $32,393 worth of Axcella Health Inc stock and bought 29,966,648 units worth $79,278,835 . The most active insiders traders include Ventures Fund Iv General Pa..., Ventures Fund Iv General Pa... et Des Produits Nestle S.A.Nes.... On average, Axcella Health Inc executives and independent directors trade stock every 31 days with the average trade being worth of $3,073,698. The most recent stock trade was executed by Margaret Koziel on 1 March 2023, trading 679 units of AXLA stock currently worth $394.
What does Axcella Health Inc do?
axcella has pioneered a new therapeutic class – defined amino acid compositions (daacs™). our daac therapeutics leverage the essential signaling function of amino acids to restore health across a network of dysregulated pathways, and provide safer solutions for patients with complex disease. with our axcellerator™ platform, we are transforming traditional drug discovery and development by generating patient data in less than a year from indication selection. this platform has delivered a rich pipeline including clinical programs in liver, metabolic, cns and orphan diseases.
What does Axcella Health Inc's logo look like?
Complete history of Shreeram Aradhye stock trades at Dicerna Pharmaceuticals Inc et Axcella Health Inc
Axcella Health Inc executives and stock owners
Axcella Health Inc executives and other stock owners filed with the SEC include:
-
Shreeram Aradhye,
Executive Vice President, Chief Development Officer -
Manu Chakravarthy,
Senior Vice President, Chief Medical Officer -
William Hinshaw,
President, Chief Executive Officer, Director -
David Epstein,
Chairman of the Board -
William R. Hinshaw Jr.,
Pres, CEO & Director -
Laurent Chardonnet,
Consultant -
William Baird,
Independent Director -
Catherine Sohn,
Independent Director -
Gary Pisano,
Independent Director -
Gregory Behar,
Independent Director -
Cristina Rondinone,
Independent Director -
Stephen Hoge,
Independent Director -
Stephen Mitchener,
Senior Vice President, Chief Business Officer -
Paul Fehlner,
Senior Vice President, Chief Intellectual Property Officer -
Heidy King-Jones,
Senior Vice President of Legal, General Counsel -
Tony Tramontin,
Senior Vice President of Research and Development , Chief Scientific Officer -
Laurent Chardonnet,
Chief Financial Officer, Senior Vice President -
Karim Azer Ph.D.,
VP of Systems Biology & Discovery -
Dr. Margaret Koziel M.D.,
Sr. VP & Chief Medical Officer -
Dr. Alison D. Schecter M.D.,
Pres of R&D -
Dr. Larry Bell,
Global Head of Regulatory Affairs & Pharmacovigilance and Sr. VP -
Virginia R. Dean,
Sr. VP & Chief People Officer -
Dr. Paul Fehlner J.D., Ph.D.,
Sr. VP, Chief Legal Officer & Corp. Sec. -
Jason Fredette,
VP of Investor Relations & Corp. Communications -
Health Science Us Holdings,...,
-
Michael Rosenblatt,
Director -
David A Berry,
Director -
Ventures Fund Iv General Pa...,
-
Paul J Sekhri,
Director -
Ventures Fund Iv General Pa...,
-
Des Produits Nestle S.A.Nes...,
-
Alison D. Schecter,
President - Research & Dev. -
Virginia R Dean,
SVP, Chief People Officer -
Margaret Koziel,
Chief Medical Officer -
Ventures Fund Iv General Pa...,
-
Robert Crane,
Chief Financial Officer -
Torben Straight Nissen,
Director -
Robert L. Rosiello,
Director